MP22-11 CHANGES IN COMORBIDITY AFTER TREATMENT WITH GONADOTROPHIN RELEASING AGONISTS VERSUS ANTI-ANDROGEN MONOTHERAPY IN MEN WITH ADVANCED NON-METASTATIC PROSTATE CANCER

INTRODUCTION AND OBJECTIVES:Studies on adverse effects of different androgen deprivation therapies (ADT) have previously focused on specific conditions (coronary heart disease, stroke, diabetes, fractures). None have reported effects on overall comorbidity. The objective of this study was to compare the increase in overall comorbidity among men receiving gonadotrophin releasing (GnRH) agonists with those on anti-androgen (AA) monotherapy (predominantly 150 mg bicalutamide daily) for advanced prostate cancer (PCa).METHODS:Men on either GnRH (n=4887) or AA (n=2078) for high risk or regionally advanced PCa were selected from the Swedish Prostate Cancer Database PCBaSE 3.0, along with age-matched PCa-free men for comparison. Incremental change in comorbidity was assessed in all study participants using the Charlson Comorbidity Index (CCI), calculated from 5yrs before through to 5yrs after the ADT start date. The difference in excess rate of CCI increase for men on GnRH agonists compared with men on AA monothe...